Annual report pursuant to Section 13 and 15(d)

CONSOLIDATED STATEMENTS OF EQUITY

v3.19.3.a.u2
CONSOLIDATED STATEMENTS OF EQUITY - USD ($)
Total
Common Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
Parent [Member]
Noncontrolling Interest [Member]
BALANCE at Oct. 31, 2017 $ 7,922,923 $ 166,028 $ 163,931,079 $ (156,174,184) $ 7,922,923
BALANCE (in Shares) at Oct. 31, 2017   16,602,759        
Stock option compensation to employees and directors 5,717,651   5,717,651   5,717,651  
Stock options and warrants issued to consultants 318,139   318,139   318,139  
Common stock issued upon exercise of stock options warrants 58,138 $ 766 57,372   58,138  
Common stock issued upon exercise of stock options warrants (in Shares)   76,636        
Restricted stock award compensation to employee pursuant to stock incentive plan 2,859,824 $ 15,000 2,844,824   2,859,824  
Restricted stock award compensation to employee pursuant to stock incentive plan (in Shares)   1,500,000        
Common stock issued to consultants 15,002 $ 53 14,949   15,002  
Common stock issued to consultants (in Shares)   5,347        
Common stock issued in at-the-market offering 2,470,182 $ 7,239 2,462,943   2,470,182  
Common stock issued in at-the-market offering (in Shares)   723,890        
Issuance of noncontrolling interest in Certainty Therapeutics, Inc. 64,656   68,974   68,974 (4,318)
Net Loss (14,243,084)     (13,996,025) (13,996,025) (247,059)
BALANCE at Oct. 31, 2018 5,183,431 $ 189,086 175,415,931 (170,170,209) 5,434,808 (251,377)
BALANCE (in Shares) at Oct. 31, 2018   18,908,632        
Stock option compensation to employees and directors 3,560,883   3,560,883   3,560,883  
Stock options and warrants issued to consultants 198,421   198,421   198,421  
Common stock issued upon exercise of stock options warrants 122,070 $ 476 121,594   122,070  
Common stock issued upon exercise of stock options warrants (in Shares)   47,600        
Restricted stock award compensation to employee pursuant to stock incentive plan 1,954,441   1,954,441   1,954,441  
Common stock issued pursuant to employee stock purchase plan 39,086 $ 116 38,970   39,086  
Common stock issued pursuant to employee stock purchase plan (in Shares)   11,650        
Common stock issued in at-the-market offering $ 5,527,428 $ 13,639 5,513,789   5,527,428  
Common stock issued in at-the-market offering (in Shares) 1,363,872 1,363,872        
Shareholder derivative complaint settlement $ 45,270   45,270   45,270  
Net Loss (11,818,652)     (11,647,054) (11,647,054) (171,598)
BALANCE at Oct. 31, 2019 $ 4,812,378 $ 203,317 $ 186,849,299 $ (181,817,263) $ 5,235,353 $ (422,975)
BALANCE (in Shares) at Oct. 31, 2019   20,331,754